Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

1.

Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

Mezil L, Berruyer-Pouyet C, Cabaud O, Josselin E, Combes S, Brunel JM, Viens P, Collette Y, Birnbaum D, Lopez M.

PLoS One. 2012;7(9):e43409. doi: 10.1371/journal.pone.0043409. Epub 2012 Sep 18.

PMID:
23028451
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.

Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, Mattei M, Lista F, Galvano F, Modesti A, Bei R.

J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):105-19.

PMID:
23489691
[PubMed - indexed for MEDLINE]
3.

Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells.

Pollock CB, Koltai H, Kapulnik Y, Prandi C, Yarden RI.

Breast Cancer Res Treat. 2012 Aug;134(3):1041-55. doi: 10.1007/s10549-012-1992-x. Epub 2012 Mar 29.

PMID:
22476848
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.

Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H.

Cancer Biol Ther. 2011 Jan 15;11(2):263-76. Epub 2011 Jan 15.

PMID:
21088503
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.

Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R.

Breast Cancer Res. 2011;13(6):R131. doi: 10.1186/bcr3077. Epub 2011 Dec 16.

PMID:
22177475
[PubMed - indexed for MEDLINE]
Free PMC Article
7.
8.

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.

Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.

Cancer Immunol Immunother. 2011 Mar;60(3):339-48. doi: 10.1007/s00262-010-0937-7. Epub 2010 Nov 18.

PMID:
21086124
[PubMed - indexed for MEDLINE]
9.

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.

Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.

Cancer Res. 2009 Nov 1;69(21):8403-11. doi: 10.1158/0008-5472.CAN-09-2146. Epub 2009 Oct 13.

PMID:
19826038
[PubMed - indexed for MEDLINE]
Free Article
10.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
11.

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL.

Cancer Res. 2007 Feb 1;67(3):1170-5.

PMID:
17283152
[PubMed - indexed for MEDLINE]
Free Article
12.

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.

Cell Cycle. 2011 Sep 1;10(17):2959-66. Epub 2011 Sep 1.

PMID:
21862872
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.

PMID:
22593441
[PubMed - indexed for MEDLINE]
15.

Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.

Cell Cycle. 2009 Jul 1;8(13):2031-40. Epub 2009 Jul 21.

PMID:
19440038
[PubMed - indexed for MEDLINE]
Free Article
16.

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.

J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33.

PMID:
14679152
[PubMed - indexed for MEDLINE]
Free Article
17.

Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.

Shieh JM, Wei TT, Tang YA, Huang SM, Wen WL, Chen MY, Cheng HC, Salunke SB, Chen CS, Lin P, Chen CT, Wang YC.

PLoS One. 2012;7(1):e30240. doi: 10.1371/journal.pone.0030240. Epub 2012 Jan 18.

PMID:
22279574
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.

Piggott L, Omidvar N, Martí Pérez S, Eberl M, Clarkson RW.

Breast Cancer Res. 2011 Sep 14;13(5):R88. doi: 10.1186/bcr2945.

PMID:
21914219
[PubMed - indexed for MEDLINE]
Free PMC Article
19.
20.

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.

J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.

PMID:
22302033
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk